361 related articles for article (PubMed ID: 18375647)
41. An exact method for analysis following a two-stage phase II cancer clinical trial.
Jovic G; Whitehead J
Stat Med; 2010 Dec; 29(30):3118-25. PubMed ID: 21170906
[TBL] [Abstract][Full Text] [Related]
42. Analysis of phase II methodologies for single-arm clinical trials with multiple endpoints in rare cancers: An example in Ewing's sarcoma.
Dutton P; Love SB; Billingham L; Hassan AB
Stat Methods Med Res; 2018 May; 27(5):1451-1463. PubMed ID: 27587590
[TBL] [Abstract][Full Text] [Related]
43. Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis.
Smith CL; Jin Y; Raddad E; McNearney TA; Ni X; Monteith D; Brown R; Deeg MA; Schnitzer T
Pharm Stat; 2019 Jan; 18(1):39-53. PubMed ID: 30321909
[TBL] [Abstract][Full Text] [Related]
44. Optimal Sequential Predictive Probability Designs for Early-Phase Oncology Expansion Cohorts.
Zabor EC; Kaizer AM; Garrett-Mayer E; Hobbs BP
JCO Precis Oncol; 2022 Mar; 6():e2100390. PubMed ID: 35385345
[TBL] [Abstract][Full Text] [Related]
45. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
Lachin JM
Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716
[TBL] [Abstract][Full Text] [Related]
46. Monitoring futility and efficacy in phase II trials with Bayesian posterior distributions-A calibration approach.
Kopp-Schneider A; Wiesenfarth M; Witt R; Edelmann D; Witt O; Abel U
Biom J; 2019 May; 61(3):488-502. PubMed ID: 30175405
[TBL] [Abstract][Full Text] [Related]
47. Phase II cancer clinical trials with heterogeneous patient populations.
Jung SH; Chang MN; Kang SJ
J Biopharm Stat; 2012; 22(2):312-28. PubMed ID: 22251176
[TBL] [Abstract][Full Text] [Related]
48. A randomized Bayesian optimal phase II design with binary endpoint.
Ding Y
J Biopharm Stat; 2023 Mar; 33(2):151-166. PubMed ID: 35793222
[TBL] [Abstract][Full Text] [Related]
49. Optimal adaptive two-stage designs for phase II cancer clinical trials.
Englert S; Kieser M
Biom J; 2013 Nov; 55(6):955-68. PubMed ID: 23868324
[TBL] [Abstract][Full Text] [Related]
50. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
Lewis RJ; Lipsky AM; Berry DA
Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
[TBL] [Abstract][Full Text] [Related]
51. A Bayesian Hybrid Adaptive Randomisation Design for Clinical Trials with Survival Outcomes.
Moatti M; Chevret S; Zohar S; Rosenberger WF
Methods Inf Med; 2016; 55(1):4-13. PubMed ID: 26404511
[TBL] [Abstract][Full Text] [Related]
52. Minimizing the maximum expected sample size in two-stage Phase II clinical trials with continuous outcomes.
Wason JM; Mander AP
J Biopharm Stat; 2012; 22(4):836-52. PubMed ID: 22651118
[TBL] [Abstract][Full Text] [Related]
53. A Bayesian decision-theoretic sequential response-adaptive randomization design.
Jiang F; Jack Lee J; Müller P
Stat Med; 2013 May; 32(12):1975-94. PubMed ID: 23315678
[TBL] [Abstract][Full Text] [Related]
54. A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage Phase II clinical trials.
Sill MW; Rubinstein L; Litwin S; Yothers G
Clin Trials; 2012 Aug; 9(4):385-95. PubMed ID: 22811448
[TBL] [Abstract][Full Text] [Related]
55. Randomized phase II trials with a prospective control.
Jung SH
Stat Med; 2008 Feb; 27(4):568-83. PubMed ID: 17573688
[TBL] [Abstract][Full Text] [Related]
56. Optimal flexible designs in phase II clinical trials.
Chen TT; Ng TH
Stat Med; 1998 Oct; 17(20):2301-12. PubMed ID: 9819829
[TBL] [Abstract][Full Text] [Related]
57. Two-stage designs optimal under the alternative hypothesis for phase II cancer clinical trials.
Mander AP; Thompson SG
Contemp Clin Trials; 2010 Nov; 31(6):572-8. PubMed ID: 20678585
[TBL] [Abstract][Full Text] [Related]
58. TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy.
Lin R; Coleman RL; Yuan Y
J Natl Cancer Inst; 2020 Jan; 112(1):38-45. PubMed ID: 30924863
[TBL] [Abstract][Full Text] [Related]
59. Randomized phase II clinical trials.
Jung SH; Sargent DJ
J Biopharm Stat; 2014; 24(4):802-16. PubMed ID: 24697589
[TBL] [Abstract][Full Text] [Related]
60. A Bayesian adaptive dose selection procedure with an overdispersed count endpoint.
Pozzi L; Schmidli H; Gasparini M; Racine-Poon A
Stat Med; 2013 Dec; 32(28):5008-27. PubMed ID: 24022748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
